Automation and artificial intelligence in the clinical microbiology laboratory
Frontiers in Cellular and Infection Microbiology · 2026
DOI: 10.3389/fcimb.2026.2000316 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2026. Verfasst von Yaodong Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory Medicine Center, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China. Hauptthemen laut MEDLINE: Artificial Intelligence, Automation, Laboratory, Laboratories, Clinical, Microbiological Techniques. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China.
Abstract (Originalsprache)
Background Clinical microbiology laboratories face persistent pressure to shorten turnaround times, reduce manual workloads, and standardize diagnostic workflows. Total laboratory automation (TLA) and artificial intelligence (AI) are complementary responses to these demands. In this review, we examine how the evidence base for automation and AI in clinical microbiology is distributed along a maturity gradient and what this distribution implies for the next phase of implementation. Content Available evidence indicates that automated platforms shorten culture turnaround times and reduce manual workload in observational and multi-center studies, although the scale of benefit depends on specimen type and workflow configuration. Automated reading, identification, and susceptibility testing systems showed high concordance with manual standards for common specimen types, with error rates below commonly cited acceptability thresholds. Evidence for AI performance in plate reading and resistance prediction is abundant; however, most models remain in an assistive phase without prospective validation. Randomized trials of rapid testing and automation rarely demonstrate overall clinical superiority, and patient-oriented benefits remain limited and inconsistent. Guidelines provide directional support, whereas interoperability, quality control, and regulatory frameworks are still under development. Summary The priority of the field is not additional single-center performance validation. The next phase requires multi-center prospective verification, interpretability, standardization, and comparative evidence with clinical outcomes as endpoints. AI-assisted evidence tools may accelerate evidence generation, although their utility remains preliminary.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory Medicine Center, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China.
- Department of Clinical Laboratory, Yumen City General Hospital (Yumen City First People's Hospital), Yumen, Gansu, China.
- Department of General Surgery, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China.
- Department of Laboratory Medicine, The First Hospital of Lanzhou University, The First School of Clinical Medicine of Lanzhou University, Lanzhou, Gansu, China.
Förderung
- National Key Research and Development Program of China
Zitieren
APA
Wang, Y., Zhang, Y., Li, N., & He, J. (2026). Automation and artificial intelligence in the clinical microbiology laboratory. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2026.2000316
Vancouver
Wang Y, Zhang Y, Li N, He J. Automation and artificial intelligence in the clinical microbiology laboratory. Frontiers in Cellular and Infection Microbiology. 2026. doi:10.3389/fcimb.2026.2000316
BibTeX
@article{Wang2026,
author = {Wang, Yaodong and Zhang, Yongxia and Li, Na and He, Jinchun},
title = {Automation and artificial intelligence in the clinical microbiology laboratory},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
doi = {10.3389/fcimb.2026.2000316}
}
EUVIMED